Fewer people each year are being diagnosed with ovarian cancer. Why do you feel the numbers are decreasing? OCRA’s Scientific Advisory Committee (SAC) is composed of doctors and researchers who are well-known and well-respected experts in the field of gynecologic oncology. They review the proposals we receive for research funding — hundreds of letters of … Continued
TODAY show contributor Jill Martin opened up about her recent breast cancer diagnosis, and urged viewers to speak with their doctors to see if genetic testing is warranted. Says Martin, “I am telling this story now because I couldn’t go through months of operations, and start to recover both physically and mentally, without shouting from … Continued
Snap summary: OCRA-funded researchers set out to improve immune response against a known therapeutic target, and provided a glimpse into a world where an ovarian cancer patient’s own immune system can be harnessed to treat and eradicate the disease. Researchers at Roswell Park Comprehensive Cancer Center have made significant gains toward immunotherapy as a viable … Continued
Janice Paulshock first began connecting with others in the ovarian cancer community in 1999 after being diagnosed with Stage 3C high-grade serous carcinoma. Twenty-plus years and four recurrences later, she remains committed to offering support to gynecologic cancer patients through her role as a mentor in OCRA’s Woman to Woman program. Find out how her … Continued
Jill McGill, reigning champion of the U.S. Senior Women’s Open, continued to champion the ovarian cancer cause at last week’s U.S. Women’s Open at Pebble Beach, handing out special ball-markers featuring her signature on one side, and a QR code leading to OCRA’s website on the other. McGill’s campaign to make a difference is in … Continued
In a new article published in Everyday Health, experts spoke about the disparities Black Americans face when diagnosed with ovarian cancer, exploring reasons why these disparities may exist, and offering recommendations for Black individuals who are diagnosed with ovarian, fallopian tube, or primary peritoneal cancer. In particular, Black Americans should be aware of the importance … Continued
Update to Clinical Guidelines: Special Circumstance Chemotherapy Approvals Last month, we reported news of an ongoing shortage of chemotherapy drugs essential to ovarian cancer treatment. Though the shortage continues, patients affected now have more options. In early June, the National Comprehensive Care Network’s (NCCN) Clinical Practice Guidelines were updated to approve oxaliplatin-based regimens like docetaxel / oxaliplatin … Continued
Summer is officially here! Strengthen your connection to community this season with special support offerings, interactive roundtables and summer-themed sessions for those impacted by ovarian and other gynecologic cancers. And no need to leave the comfort of your climate-controlled home to attend — all meetings will be held online. “This summer, we’re offering more choices … Continued
Share your thoughts on multi-cancer detection tests and what role they might have, or not, for ovarian cancer? OCRA’s Scientific Advisory Committee (SAC) is comprised of doctors and researchers who are well-known and well-respected experts in the field of gynecologic oncology. They review the proposals we receive for research funding — hundreds of letters of … Continued
Being a professional athlete takes immense focus and determination — traits that pro golfer and defending champion of the U.S. Senior Women’s Open Jill McGill is harnessing to take on a challenge of another type: raising awareness about ovarian cancer. Her motivation? Two of the people whom she holds most dear. “My sister is a … Continued
Diagnosed with ovarian cancer in 2022, Marsha Biven currently participates in a number of OCRA programs, including Staying Connected, Survivors Teaching Students, and Woman to Woman. Read on to learn more about her story, including how a vision board (and a rogue parakeet!) factored into her experience and why her professional background is an asset … Continued
This action alert has now expired. This shortage of chemotherapy drugs, including cisplatin and carboplatin, has reached a serious level, impacting the treatment options available to some ovarian cancer patients. But you can help. In response, Representatives Ami Bera (D-CA), Mike Kelly (R-PA), Derek Kilmer (D-WA), and Brian Fitzpatrick (R-PA) have authored a Dear Colleague … Continued
Get email updates about research news, action alerts, and ways to join the fight.
